Floatz logo

Ambroxol

Type I Gaucher Disease

Exsar CorporationSmall moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Type I Gaucher Disease cohort.

Asset / SponsorPhaseRating
Cerezyme
Sanofi
Phase 4A
Velaglucerase Alfa
Baylor Research Institute
Phase 4BB
Cerezyme
Sanofi
Phase 3BB
Eliglustat
Sanofi
Phase 3BB
Miglustat
Actelion
Phase 3BB

View all 13 →

Same molecule, other indications

Ambroxol is also rated in:

Parkinson diseaseDormant
BB
Indicative ·
65 / 100
View asset →
GBA1-related Parkinson disease, susceptibilityDormant
BB
Indicative ·
64 / 100
View asset →
mucus inspissation of respiratory tractDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →